成都粥样下肢动脉硬化斑块哪家医院好成都治疗下肢静脉血栓哪个医院,成都手术治疗静脉曲张需要多少钱,成都做静脉扩张手术得多钱,成都医院治疗腿部血管炎,成都前列腺肥大怎样能治好,成都治疗精索静脉曲张专门医院,成都有没有精索静脉曲张专科医院

WASHINGTON, Nov. 14 (Xinhua) -- A novel study in twins found that exposure to trichloroethylene (TCE) -- a hazardous organic contaminant found in soil, groundwater, and air -- is significantly associated with increased risk of Parkinson's disease (PD). Possibility of developing this neurodegenerative disease is also linked to perchloroethylene (PERC) and carbon tetrachloride (CCI4) exposure, according to the study appearing in Annals of Neurology on Monday.The National Institute of Neurological Disorders and Stroke estimates that as many as 500,000 Americans have PD and more than 50,000 new cases are diagnosed annually. While there is much debate regarding cause of PD, studies suggest that genetic and environmental factors likely trigger the disease. Several studies have reported that exposure to solvents may increase risk of PD, but research assessing specific agents is limited.The current epidemiological study, led by Samuel Goldman and Caroline Tanner with The Parkinson's Institute in Sunnyvale, California, investigated exposure to TCE, PERC and CCI4 and risk of developing PD. The team interviewed 99 twin pairs in which one twin had PD and one didn't, inquiring about lifetime occupations and hobbies. Lifetime exposures to six specific solvents previously linked to PD in medical literature -- n-hexane, xylene, toluene, CCI4, TCE and PERC -- were inferred for each job or hobby.The findings are the first to report a significant association between TCE exposure and PD -- a more than six-fold increased risk. Researchers also found that exposure to PERC and CCI4 tended toward significant risk of developing the disease. "Our study confirms that common environmental contaminants may increase the risk of developing PD, which has considerable public health implications," commented Goldman in a statement.TCE, PERC and CCI4 have been used extensively worldwide, with TCE noted as a common agent in dry-cleaning solutions, adhesives, paints, and carpet cleaners. Despite the U.S. Food and Drug Administration (FDA) banning the use of TCE as a general anesthetic, skin disinfectant, and coffee decaffeinating agent in 1977, it is still widely used today as a degreasing agent. In the U.S., millions of pounds of TCE are still released into the environment each year and it is the most common organic contaminant found in ground water, detected in up to 30 percent of drinking water supplies in the country.In a release issued on Sept. 28, 2011, the Environmental Protection Agency announced that TCE is carcinogenic to humans.

SHANGHAI, Jan. 11 (Xinhua) -- The listed arm of China's biggest train maker, China South Locomotive and Rolling Stock Industry (Group) Corporation (CSR), has been allowed by regulatory authorities to raise 9 billion yuan (1.41 billion U.S. dollars) on the stock market, the company said Wednesday.The Hong Kong- and Shanghai- listed CSR Corp. Ltd. will sell 1.96 billion shares at 4.46 yuan apiece to select investors, it said. But CSR's parent -- state-owned CSR Group -- has agreed to buy no less than 6 billion yuan's worth of the shares, leaving the rest to institutional investors.CSR's net profit growth in the third quarter of 2011 plunged to 9.66 percent year-on-year from a high of 85.08 percent in the first half of 2011 as the country put the brakes on development of the railway sector after a deadly bullet train crash on July 23 that killed 40 people and injured 210 others.The decision to slow the development of high-speed rail lines has led to halts in construction of about 90 percent of ongoing railway projects, or 10,000 km of rail lines across the country, local media reported earlier.CSR is the maker of the bullet trains involved in last July's deadly collision. After the accident, the company's executives bought a combined 540,000 share in August, a move seen as an attempt to bolster battered stock prices.Analysts say the fundraising would help CSR greatly ease its financial burdens. The company earlier pledged to maintain profit growth and its dividend policy to boost investors' confidence.

BEIJING, Dec. 10 (Xinhua) -- Pharmaceutical producers will risk having their operation license revoked if they use prohibited chemicals as medicine ingredients or involved in fake drug production, China's drug regulator said in a circular Saturday.The State Food and Drug Administration said it would name and shame pharmaceutical companies if they make phoney medicine and withdraw the operation licenses of pharmacies if they intentionally sell unqualified drugs.The circular came in the wake of several counterfeit medicine scandals uncovered by Chinese police in the past few months.On Nov. 4, police seized more than 65 million imitation medicinal tablets and arrested 114 suspects in a cross-provincial raid on counterfeit drugs.In October, police raided on an illegal drug production and sale network and ended up with the seizure of 190 million yuan (29.9 million U.S. dollars) worth of counterfeit drugs.The suspects were found to have used starch or corn powder as ingredients for bogus medicine, or re-packaged expired pharmaceuticals.Police also found animal feed and chemical pigments in the counterfeit products.

JAKARTA, Oct. 6 (Xinhua) -- United Nations Children's Fund (UNICEF) representative for Indonesia Angela Kearney said on Thursday that Indonesia's infant mortality rate is still high although it showed a downward trend in the past few years, local media reported.Based on a UNICEF global child mortality report, over the past 10 years infant mortality rate declined significantly to 35 out of every 1,000 births in 2011 from 97 out of every 1,000 births in 1991, she said at workshop on household to hospital cantinuum care held in Makassar, South Sulawesi.The achievement was inseparable from the central and regional government's endeavors, she said.After all, the results of a health demography survey showed 193, 000 children lost life chance every year before they reached the age of 5 years, she said.In South Sulawesi alone, 17.3 out of every 1,000 newborns died before they reached the age of 28 days last year. Two-thirds of the deaths occurred on the first week of their life and one out of every four mothers gave birth to their children without the help of trained medical workers.Mothers' poor access to health facilities in the country posed one of the obstacles to the promotion of the nation's health. One out of every five mothers came from poor families, she said.She said that a lack of infrastructures and equipment and the low number of trained medical workers had hindered the fulfillment of health services, the Antara news service said.To deal with the challenge, the method of providing health services must be improved and the support of trained medical workers must be increased, she said."I am very happy to see UNICEF cooperating with the South Sulawesi provincial government to develop comprehensive approaches to overcome the shortcomings at social level and public health system at provincial health facilities," she said.

WASHINGTON, Dec. 7 (Xinhua) -- Drugs that affect the levels of an important brain protein involved in learning and memory reverse cellular changes in the brain seen during aging, according to an animal study published Wednesday in the Journal of Neuroscience. The findings could one day aid in the development of new drugs that enhance cognitive function in older adults.Aging-related memory loss is associated with the gradual deterioration of the structure and function of synapses (the connections between brain cells) in brain regions critical to learning and memory, such as the hippocampus.Recent studies suggested that histone acetylation, a chemical process that controls whether genes are turned on, affects this process. Specifically, it affects brain cells' ability to alter the strength and structure of their connections for information storage, a process known as synaptic plasticity, which is a cellular signature of memory.In the current study, Cui-Wei Xie, of the University of California, Los Angeles, and colleagues found that compared with younger rats, hippocampi from older rats have less brain-derived neurotrophic factor (BDNF) -- a protein that promotes synaptic plasticity -- and less histone acetylation of the Bdnf gene. By treating the hippocampal tissue from older animals with a drug that increased histone acetylation, they were able to restore BDNF production and synaptic plasticity to levels found in younger animals."These findings shed light on why synapses become less efficient and more vulnerable to impairment during aging," said Xie, who led the study. "Such knowledge could help develop new drugs for cognitive aging and aging-related neurodegenerative diseases, such as Alzheimer's disease," she added.